Mr Harwood is a healthcare industry advisor for Avista Capital Partners, a private equity firm. Prior to working with Avista, Mr Harwood was president and CEO of privately-held Focus Diagnostics.
Mr Harwood also serves on the board of directors at BioReliance, a contract research organization specializing in biological safety testing and specialized toxicology, RadPharm, a privately-held contract research organization located in Princeton, New Jersey, and Itero Biopharmaceuticals, a development stage company located in the San Francisco Bay Area.
William Clarke, president and CEO of Cellectar, said: “Charlie brings exceptional financial and transaction expertise to the Cellectar board. His years of experience in the drug development industry will prove beneficial to the company as we advance our radiopharmaceutical products toward clinical testing and commercialization.”